Conversely, apatinib, a new oral tyrosine kinase inhibitor that targets VEGF signaling, can inhibit the Nrf2–HO-1 pathway to exhaust the cellular glutathione reservoir and thereby significantly elevate intracellular ROS levels, leading to apoptosis and autophagy in ovarian cancer cells [148]. Here, HMOX1 is linked to ovarian carcinoma.